AI Models & Platforms
Oracle Introduces AI Agents to Coordinate Clinical Trial Operations

Key PointsOracle's clinical trial agents recommend actions but require human approval before…
View more
- Oracle's clinical trial agents recommend actions but require human approval before execution.
- The agents coordinate across Oracle Life Sciences applications and supported third-party data sources.
- Oracle plans to extend agentic assistance into clinical data management and post-market workflows.
Oracle introduced Oracle Life Sciences AI Agents on November 18, 2026, making an AI-assisted coordination layer for clinical trial operations available to early adopters. The agents initially focus on portfolio monitoring, trial planning, and trial conduct, with proposed actions subject to human review and approval.
The agents bring together insights from Oracle Life Sciences applications and supported third-party data sources. They are designed to identify operational issues, recommend actions, and coordinate responses across clinical development workflows that span studies, applications, data, and teams.
Monitoring with Human Approval
An agent can monitor study performance and the likely drivers of variances in key performance indicators, then recommend operational actions that follow the trial protocol. That example links detection of a performance change to a proposed response, giving trial teams a specific operational use for the agent layer.
Humans remain responsible for reviewing recommendations and approving proposed actions before execution. The approval requirement gives the initial product a bounded role: it can surface an issue and organize a suggested response, while the decision to execute stays with a human reviewer.
Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, said the aim is to “monitor performance, identify emerging risks, and coordinate responses across the trial lifecycle.” The offering combines Oracle’s Life Sciences applications, AI-assisted capabilities, connected data services, and cloud infrastructure.
Existing Clinical Trial Systems
The agents fit into an established clinical trial operations portfolio covering portfolio planning, study startup, electronic trial master file management, and clinical trial management. Those unified applications run through Oracle Cloud Infrastructure and support systems integration, automation, and operational analytics.
Oracle Life Sciences CTMS, its clinical trial management system, centrally tracks study activities, site performance, and regulatory documentation. Interoperability with electronic data capture and electronic trial master file systems supports data integrity and oversight across a research portfolio.
That application landscape gives context to the emphasis on coordination. Planning, startup, documentation, and trial management already occupy distinct workflows; the agent layer is intended to draw operational intelligence across applications and supported external sources, then present recommendations for review.
Expansion Beyond Trial Conduct
The wider Oracle Life Sciences platform serves sponsors, contract research organizations, and research sites. It also spans clinical trial data collection, pharmacovigilance, or drug-safety monitoring, and data intelligence, with embedded AI and analytics supporting study design and execution.
Oracle plans to extend the AI-assisted capabilities into clinical data management, post-trial analytics, trial design, and post-market workflows. Those are roadmap items rather than functions included in the initial early-adopter release, and they would carry agentic assistance beyond the conduct of an active study.
The early-adopter product consequently centers on operational coordination rather than autonomous trial management. Human approval controls execution in the initial release, while Oracle’s roadmap points toward extending that supervised model across a wider set of clinical research and post-market workflows.












